{"name":"RANBAXY","slug":"ranbaxy","ticker":"","exchange":"","domain":"ranbaxy.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1990-01-01","label":"Ultravate first approved","drug":"Ultravate","drugSlug":"ulobetasol-propionate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ANTARA® (fenofibrate)","genericName":"ANTARA® (fenofibrate)","slug":"antara-fenofibrate","indication":"Hypertriglyceridemia","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ultravate","genericName":"ulobetasol propionate","slug":"ulobetasol-propionate","indication":"Plaque Psoriasis","status":"marketed"}]}],"pipeline":[{"name":"ANTARA® (fenofibrate)","genericName":"ANTARA® (fenofibrate)","slug":"antara-fenofibrate","phase":"marketed","mechanism":"Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and increase HDL cholesterol.","indications":["Hypertriglyceridemia","Mixed dyslipidemia","Primary hypercholesterolemia"],"catalyst":""},{"name":"Ultravate","genericName":"ulobetasol propionate","slug":"ulobetasol-propionate","phase":"marketed","mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation.","indications":["Plaque Psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}